Adult T-cell acute lymphoblastic leukemia: Prognostic impact of myeloid-associated antigens

Expert Review of Hematology

Volumn 2, Issue 1, 2009, Pages 27-29

  Perbellini, Omar ^a   Scupoli, Maria Teresa ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Adult T cell acute lymphoblastic leukemia; Myeloid antigen

Indexed keywords

ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANTIGEN EXPRESSION; BONE MARROW CELL; CANCER RISK; HUMAN; MAJOR CLINICAL STUDY; NOTE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; T CELL LEUKEMIA;

EID: 77953371068     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474086.2.1.27     Document Type: Note

References (9)

1. Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat. Rev. Immunol. 8, 380-390 (2008).
2. Chiaretti S, Li X, Gentleman R et al. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood 103, 2771-2778 (2004).
3. Khabori M, Samiee S, Fung S et al. Adult precursor T-lymphoblastic leukemia/ lymphoma with myeloid-associated antigen expression is associated with a lower complete remission rate following induction chemotherapy. Acta Haematol. 120, 5-10 (2008).
4. Vitale A, Guarini A, Ariola C et al. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood 107, 473-479 (2006).
5. Suggs JL, Cruse JM, Lewis RE. Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias. Exp. Mol. Pathol. 83, 471-473 (2007).
6. Vitale A, Guarini A, Ariola C et al. Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. Haematologica 92, 342-348 (2007).
7. Campana D. Determination of minimal residual disease in leukaemia patients. Br. J. Haematol. 121, 823-838 (2003). (Pubitemid 36760300)
8. Krampera M, Vitale A, Vincenzi C et al. Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. Br. J. Haematol. 120, 74-79 (2003).
9. Golay J, Di Gaetano N, Amico D et al. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br. J. Haematol. 128, 310-317 (2005).